the questions, answered short and sourced
Tesamorelin FAQ: common questions, cited answers.
Short, direct answers about tesamorelin's identity, mechanism, regulatory scope, and safety — each drawn from the published record.
What is tesamorelin?
Tesamorelin is a synthetic 44-amino-acid analogue of human growth hormone-releasing hormone, GHRH(1-44), bearing an N-terminal trans-3-hexenoic acid group that resists DPP-IV cleavage [1]. It is the only FDA-approved agent in its class, indicated solely to reduce excess abdominal fat in HIV-associated lipodystrophy [6].
What does tesamorelin do?
It stimulates the pituitary to release the body's own pulsatile growth hormone, which raises hepatic IGF-1 and preferentially drives lipolysis in visceral fat [2]. In trials it reduced visceral adipose tissue and hepatic fat without supplying exogenous growth hormone [3][5].
How does tesamorelin work?
Tesamorelin binds the GHRH receptor on pituitary somatotrophs, activating the Gs/adenylyl-cyclase/cAMP/PKA cascade to synthesize and secrete endogenous growth hormone; growth hormone then drives hepatic IGF-1 production and visceral-fat lipolysis [2]. The trans-3-hexenoic acid modification blocks DPP-IV inactivation [1].
Is tesamorelin a growth hormone?
No. Tesamorelin is a GHRH analogue — a secretagogue that prompts the pituitary to release the body's own growth hormone; it is not exogenous recombinant growth hormone and amplifies natural pulsatile secretion rather than replacing it [9].
Is tesamorelin FDA approved?
Yes, but narrowly: tesamorelin was FDA-approved in 2010 (NDA 022505) solely to reduce excess abdominal fat in HIV-infected adults with antiretroviral-related lipodystrophy [6]. Every other use — including general or cosmetic fat loss, anti-aging, and performance — is off-label and not FDA-approved.
Will tesamorelin make you stronger?
No strength or performance endpoint has been established in controlled trials. The studied effects are on visceral and hepatic fat, IGF-1, and (in one aging trial) executive function [3][5][8]; muscle-strength or athletic-performance claims are not supported by the literature, and tesamorelin is WADA-prohibited in sport (S2).
Does tesamorelin increase the risk of diabetes or affect blood sugar?
In 13 healthy men, two weeks of tesamorelin left fasting glucose (P=0.93) and insulin-stimulated glucose uptake (P=0.61) unchanged [7], and the 52-week HIV program reported no clinically significant glucose changes [4]. Modest glucose perturbation can occur as a growth-hormone-class effect, so monitoring is warranted in prediabetes or dysglycemia.
What are the side effects of tesamorelin?
Reported effects center on injection-site reactions and growth-hormone-class effects (fluid balance, arthralgia, modest glucose perturbation) plus elevated IGF-1 [15]. The NIH LiverTox monograph assigns a likelihood score of E (unlikely cause of liver injury) [6]; active malignancy, hypersensitivity, and pregnancy are contraindications on the FDA label [15].
Does tesamorelin cause water retention?
Fluid retention is a recognized growth-hormone-class effect, reflecting growth-hormone/IGF-1 axis stimulation; the FDA label carries warnings about stimulating endogenous growth hormone and raising serum IGF-1 [15], and reviews list peripheral oedema and arthralgia among growth-hormone-associated events. Severity in trials was generally mild.
Who should not take tesamorelin / who should avoid it?
The FDA label contraindicates use in active malignancy (treatment must be complete and the malignancy inactive), known hypersensitivity to tesamorelin or excipients, and pregnancy — animal organogenesis studies showed hydrocephaly in offspring [15]. Research-grade material is not for human self-administration.
Is tesamorelin a steroid?
No. Tesamorelin is a synthetic GHRH(1-44) peptide analogue — a chain of amino acids that acts at the cell-surface GHRH receptor to trigger the body's own growth-hormone release [2] — not an anabolic steroid, which is a lipid molecule acting on intracellular hormone receptors. The two share neither structure nor mechanism.
Does tesamorelin raise IGF-1 levels?
Yes. By stimulating endogenous growth hormone, tesamorelin raises hepatic IGF-1: +81.0% in the pivotal HIV trial [3], +181 ug/L in healthy men [7], and +117% in the older-adult cognition trial [8]. IGF-1 elevation is the principal pharmacodynamic marker and the basis for growth-hormone-class warnings.
How does tesamorelin stimulate growth hormone release?
It binds the Gs-coupled GHRH receptor on pituitary somatotrophs, raising cAMP via adenylyl cyclase, activating PKA and CREB-driven growth-hormone gene transcription, and triggering granule exocytosis — so growth hormone is released in the body's natural episodic, pulsatile pattern [2].
Can tesamorelin improve cognitive function in older adults?
A 20-week RCT of 152 older adults (66 with mild cognitive impairment) reported that GHRH/tesamorelin 1 mg/day improved executive function (P=0.005) with a verbal-memory trend (P=0.08) and raised IGF-1 by 117% [8]; a linked imaging substudy found increased brain GABA and NAAG with decreased myo-inositol alongside the effect [10]. This is the strongest non-HIV cognition signal — but it is a single trial.
Will tesamorelin help me lose belly fat?
In HIV patients with abdominal fat accumulation, tesamorelin 2 mg/day reduced visceral adipose tissue by 15.2% at 26 weeks (vs +5.0% placebo) [3]. Efficacy outside HIV-associated lipodystrophy is mechanistically plausible but not established by large RCTs; research-grade material is for laboratory study only.
How long does it take to see fat loss from tesamorelin?
In the pivotal trials, significant visceral-fat reduction was measured at 26 weeks and sustained at -18% through 52 weeks of continued dosing [3][4]; visceral fat reaccumulated within weeks of discontinuation [4].
Does tesamorelin burn belly fat?
Trials show selective reduction of visceral (intra-abdominal) fat rather than subcutaneous fat or overall BMI; a 2026 meta-analysis of five RCTs reported pooled visceral-fat reduction of -27.71 cm2 [13]. The mechanism is growth-hormone/IGF-1-driven lipolysis, studied only in HIV-associated lipodystrophy [2].
Does tesamorelin work for fat loss in non-HIV users?
Pivotal efficacy trials were conducted in HIV-positive adults on antiretroviral therapy [3][4]; non-HIV human data are limited to a mechanistic study in healthy men [7] and a cognition trial in older adults [8]. No large general-population fat-loss RCT has been completed, so non-HIV efficacy is unestablished and off-label.
Is tesamorelin a potential treatment for non-alcoholic fatty liver disease?
In a 6-month JAMA RCT of antiretroviral-treated HIV adults, tesamorelin reduced hepatic lipid-to-water percentage by a net -2.9% (P=0.003) alongside a visceral-fat reduction [5]. Reviews of HIV-associated NAFLD list it among promising therapies [11], but its only approved indication remains HIV-associated lipodystrophy [6].
How does tesamorelin affect the liver in NAFLD?
Beyond lowering hepatic fat (net -2.9% in the JAMA trial) [5], the growth-hormone/IGF-1 axis is thought to drive the benefit indirectly through visceral-fat reduction; reviews of HIV-associated fatty liver disease identify visceral adiposity as a major driver of fibrosis risk and list tesamorelin among promising interventions [11].
Can tesamorelin reduce liver fat?
Yes, in the studied HIV population: a JAMA RCT reported a net hepatic-fat reduction of -2.9% (P=0.003) [5], and a 2026 meta-analysis of five RCTs reported a pooled hepatic-fat-fraction reduction of -4.28% [13].
What is the half-life of tesamorelin?
Plasma exposure is short. Population PK modeling reported apparent clearance ~1,060 L/h; secondary sources (FDA label, Mayo Clinic) describe a terminal half-life on the order of ~26-38 minutes [12]. Downstream IGF-1 elevation persists across the dosing interval, supporting once-daily dosing.
How long does tesamorelin stay in your system?
The peptide itself clears rapidly from plasma (clearance ~1,060 L/h), but its biological effect — IGF-1 elevation — persists over the once-daily interval [12]. The absorbed fraction rose roughly 13% by day 14 versus day 1 in population-PK analysis [12].